It has gone to court- Faros have 3 attorneys who made an
It has gone to court- Faros have 3 attorneys who made an appearance -they asked for an extended time to reply and were given to July 5 to reply
nnlx was given extended time to reply to june 24 but I havent seen their reply brief-and getting ahold of these things is not as easy as it use to be before Big brother etc
not completely sure by what you mean as not there- investors use otc exchange to learn about companies-nnlx is still listed there
100's of posts talked about the otc info upgrades etc- last nnlx comm indicated nnlx would be upgrading as per otc- - but some things happened-including what we learned about brets heart attack - i thought he had gone back to work as somebody reported - but once he was incapacitated there was nobody to donate their time to keep the business going bc the company had not yet achieved profitability
true you cant force a response- there are thousands of pink co's and were as high as c 900 no info co's-many of them disappear this way-very few communicate w stockholders as they should
the relatively rapid changes to the otc exchange since 2009 make it harder for the co's who dont have enough money to meet all the new rules etc
and such ceos rarely know the otc exchange as much as they should
the rules have changed over time -and now co's without enough money to get going without stock issuances should seriously re-think their public entrance into the otc -
there are also many growing mutant groups who continuously siphon money off of stock value making it very difficult for co's to raise money- so the game has seriously changed since 2009
to the point where its very difficult for longs to make money- due to the arrogant mutants etc longs are the fall guy which keeps the market going- to help my best friend who dragged me into pennies i read scores of thousands of pages re the penny market and co's disclosures etc-
and could not find an honest way for longs to make money anymore - except find a hidden gem w an actual product and reasonable catalysts etc- there were co's w market price of as high as 20 dollars /share without a product-many co's promised big things but didnt even have a product or the money to create a product
nnlx didnt have the money - they tried many ways to raise money but all seemed to fail to raise enough money
over 90% of startups fail- nnlx at least had a good product and patents- talked about all this before- the world is no longer predictable - covid shut schools etc which were nnlx's potential net moneymaker etc
you increasingly have to be independently wealthy to get such startups going -and if thats the case there is no reason to enter into all the headaches that come w a publicly reporting co nowadays
1
1
Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...
Continue Reading
Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...
Continue Reading
A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...
Continue Reading
Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...
Continue Reading
A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...
Continue Reading
Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...
Continue Reading
A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...
Continue Reading
Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...
Continue Reading
Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...
Continue Reading
China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...
Continue Reading
Top 5 Most Recently Viewed Articles
Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.
Continue Reading
Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...
Continue Reading
Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...
Continue Reading
NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...
Continue Reading
Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...
Continue Reading